Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

about

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

Item

http://www.wikidata.org/entity/Q58132004

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2018

@uk

name

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

@en

Promoting Precision Addiction Management

@nl

type

Item

label

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

@en

Promoting Precision Addiction Management

@nl

prefLabel

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

@en

Promoting Precision Addiction Management

@nl

P1476

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

@en

P2093

Bruce Steinberg

http://www.w3.org/2001/XMLSchema#string

David Baron

http://www.w3.org/2001/XMLSchema#string

David Siwicki

http://www.w3.org/2001/XMLSchema#string

Edward J Modestino

http://www.w3.org/2001/XMLSchema#string

Eric R Braverman

http://www.w3.org/2001/XMLSchema#string

Jennifer Neary

http://www.w3.org/2001/XMLSchema#string

Kenneth Blum

http://www.w3.org/2001/XMLSchema#string

Marjorie C Gondré-Lewis

http://www.w3.org/2001/XMLSchema#string

Mark Moran

http://www.w3.org/2001/XMLSchema#string

Mary Hauser

http://www.w3.org/2001/XMLSchema#string

P2860

Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors

Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions

Reward deficiency syndrome: genetic aspects of behavioral disorders.

The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery.

Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.

Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence.

New concepts in cocaine addiction: the dopamine depletion hypothesis.

Clonidine blocks acute opiate-withdrawal symptoms.

P304

1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.26717/BJSTR.2018.02.000738

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30370423

http://www.w3.org/2001/XMLSchema#string

P921

opioid

P932

6201280

http://www.w3.org/2001/XMLSchema#string